New fund targets companies battered by market doubts
Record low biotech valuations have prompted a new VC investor to start shopping with a planned $200 million fund.
Lou Panaccio Patrick Davies Chris Behrenbruch Glenn Haifer Telix Pharmaceuticals Neuren Pharmaceuticals
Source: afr.com